Treatment of functional bowel disorders of irritable bowel-type (IBS) in children remains a difficult task because of a lack of drugs with low U. Martens 1 P. Enck 1 adverse event profile. We here report the results of a treatment study E. Zieseniß 2 in 203 children (66 boys and 137 girls) age 4 to 18 years (mean: 10.5±4.5 years) with typical IBS symptoms with abdominal pain and either predominant diarrhea (n=50), constipation (n=56), alternating
Introduction
The irritable bowel syndrome (IBS) is a functional bowel disorder and characterized by a number of symptoms including abdominal pain or discomfort and disturbed bowel habits. Other typical IBS symptoms are diffuse abdominal pain, bloating, excessive passing of gas, irregular bowel movements with improvement of symptoms after defecation, and/or the feeling of incomplete evacuation. Morphological abnormalities are missing that sufficiently could explain the symptoms, as are diagnostic criteria and proven pathophysiological concepts; hence a therapeutic concept based on such findings is lacking as well. The diagnosis is usually based of the recording of the typical symptom pattern, the absence of alarm symptoms, and the exclusion of a number of differential diagnoses. In the present observational study, the recently published diagnostic criteria of the Rome III consensus for IBS have been applied [1] , [2] , (Table 1) . This classification was meanwhile also applied to childhood functional bowel disorders [3] and has replaced the older terminology that used "recurrent abdominal pain" as diagnostic label [4] . IBS is a frequent disease in the general population. The worldwide prevalence ranged between 10 and 20% in the adult and adolescent population, and women are more often affected than men. The disease has substantial consequences on quality-of-life of patients and induces high direct and indirect medical costs [5] . For pediatric patients, very few data are available. The recently published children and adolescent health survey (KIGGS) collected -among others -representative data on pain in children age 3-17 years in Germany [6] . In children between 3 and 10 years, "belly pain" was the most frequent pain location, while children age 11 to 17 most frequently reported headaches, followed by abdominal and back pains [7] . Non-medicinal general management strategies including exercises, stress reduction, and relaxation techniques may serve as supplementary options in addition to drug therapy of key symptoms, e.g. regulation of stool consistency, against bloating, spasmolytic therapy and modulation of gastrointestinal motility. Only a few new drug developments have found their way into clinical routine in the last years [8] , but most have never been tested in children. Since a number of years, prebiotic and probiotic therapies have seen a renaissance [9] in clinical use and are most often used in functional gastrointestinal disorders [10] . Their low adverse event profile [11] also supports their use in childhood functional bowel disorders but respective studies are rather scarce [12] -they are mostly used with dermatological and allergic diseases [13] . Symbioflor ® 2 (SF2) (SymbioPharm GmbH, Herborn, Germany) contains both living as well as non-living Escherichia coli bacteria (cells and autolysate of 1.5-4.5x10 7 bacteria) and is -based on current knowledge -effective in the therapy of functional bowel disorders [14] . We here report the open label use of SF2 in 203 children age 4 to 18 with IBS symptoms according to Rome-III criteria. 
Patients and methods

Type of study
This is an observational study (Anwendungsbeobachtung, AWB) according to §67-6 of the respective law (Arzneimittelgesetz, AMG) in Germany. The study was conducted according to the "Recommendations for planning and conductance of observational studies" (Empfehlungen According to the respective rules, the study did not interfere with medical routine in treatment of childhood abdominal pain but left the management up to the doctor's decision; this included also the dosage and the duration of treatment, and eventually needed supplementary therapy. Doctors were asked to document each patient's data (age, gender, height. weight) and treatment with SF2 during the course of the study. Retrospective inclusion of patients was not permitted. Patients that fulfilled inclusion and exclusion criteria (Table 1 ) but were not treated by SF2 were also documented. The current observational study did not legally require informed consent of patients and their parents, respectively in addition to what is required with every medical intervention, since patients received a therapy based on the doctors sole decision, and no additional risk was involved, data storage and statistical evaluation is allowed in routine praxis as well. Only anonymous data were used for evaluation that did not interfere with legal requirements regarding handling of personalized data and the medical confidentiality rules of the doctor. According to §67-6 of the AMG, the conductance of the study was registered with the legal representative of private practitioners in Germany (Kassenärztliche Bundesvereinigung), the German drug approval authorities (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) and the association of health insurances (Spitzenverbände der Krankenkassen). The study was conducted with an approved medical product. According to AMG, this requires prescription of the drug by a doctor and the usage of regular commercially available products, in addition to individual indication and patient selection. 
Doctors and patients
General course of study, duration, dosage
Children age 4 to 18 with IBS that would receive SF2 anyway were to include into the study. It was required to observe the children until significant improvement of symptoms had occurred but for a maximum of 3 months. SF2 had to be used according to the doctors prescription. The doctor was also asked to document the duration of therapy and the dosage prescribed. The regular dosage in children -as indicated on the patient information sheet -is 1x10 drops/day diluted in water and taken midday, but in adolescents the dosage can be increased up to the adult dosage (30 drops/day). Because of the non-interfering character of the observational study, neither the type nor the timing of subsequent doctor visits were ruled, and their number and intervals was left up to the individual decision of the treating doctor. However, to be able to estimate the treatment success, it was advised to conduct and intermediate office consultation about 2 weeks after the initial visit, and a final examination after 3 months. The intermediate consultation could also be used to eventually adjust the drug dosage. The investigations to perform at the single visits are listed in Table 2 .
Symptom documentation
At any office visit, the presence and severity of the following IBS symptoms were registered: number of stools (per day or per week), stool consistency (hard/lumpy, formed, soft/mushy, liquid, alternating), mucus with stool (yes/no), Table 2 : Clinical investigations during the observational study abdominal pain (yes/no), bloating (yes/no), passing of gas (yes/no), passage of stools (yes/no). Doctors were also asked to overall estimate the treatment success between "very good" and "poor", and parents and adolescent patients were asked to compare SF2 treatment with previous therapies used and to evaluate SF between "much better" and "much worse". Doctors and parents/patients were also asked to evaluate the overall tolerability and any adverse event between "very good" and "unacceptable".
Statistical evaluation
For the analysis, all documented evaluation sheets were used, and all patients were included (intent-to-treat analysis, ITT). Documented variables are presented with their descriptive values (mean, standard deviation), or as distribution tables in case of qualitative variables. Inference statistics must be regarded as exploratory and non-confirmatory.
Results
Demographics and diagnoses
A total of 203 children and adolescents in two age groups (4 to 11 years and 12 to 18 years) participated in the study and were distributed unequally among the four clinical subtypes of IBS: pain and diarrhea (n=50), pain and constipation (n=56), pain and alternating bowel habits (n=28) and unspecified pain (n=68). All children suffered from IBS according to the Rome III classification (Table 3) . Table 3 shows the key demographic variables gender, age, height and weight of all patients grouped by age and clinical IBS type. There were no differences noted between the four IBS subtypes with respect to gender, age, and height and weight (age-adjusted). An IBS diagnosis according to the Rome III classification requires at least 2 months of symptom persistence; accordingly, the doctors participating in this study started treating IBS in the patients after an average 80 days. However, substantial differences occurred depending on the type of IBS symptoms: in general, diarrhea-predominant and constipation-predominant IBS were treated relatively early (median less than 100 days) while IBS alternating and unspecified IBS were started being treated after more than 100 days ( Table 3) .
Dosage of SF2, other medication
In 77.4% of cases, patients received the standard children dosage of 1x10 drops per days of SF2, and change of dosing was rare (5% of cases). Only 6 patients received other medication in addition to SF2, and usually for a few days only: 4 x lactulose, 1 x Gastrosil 
Duration of treatment
Mean treatment duration with SF2 ranged between 40 and 50 days in both age groups and all types of IBS (Table  3) , with the exception of "unspecified IBS": these patients were treated an average of 34.2 days. Differences Table 4 summarizes the efficacy of SFG2 treatment for the core IBS symptoms abdominal pain and stool frequency (see above) between initial and final examination, broken down by age groups and IBS types. All changes are significant (p<.001). Also, other IBS associated symptoms such as bloating, passage of gas, mucus in stools and altered stool passage (urge, need for straining) were significantly improved with SF2 (p<.001) ( Table 5 ). Table 5 also summarizes the global assessment of treatment efficacy by the doctor. In the majority of cases (81.8%) the therapy was judged as "very good" or "good". This is valid for all age groups and all clinical IBS types, with the exception of the IBS alternators age 12 to 18, where doctors evaluated only 55.5% of therapies as "good" or better. However this refers only to a very small number of patients (n=9). 
Efficacy of therapy
Global assessment of efficacy
Comparison with previously used medication
Only about 40% patients/parents made respective evaluations thus had experience with other IBS therapies. SF2 was judged as better in 77% of cases, and in only a very few instances, SF2 was regarded as "rather worse" or "much worse" than the comparator drug, with no differences between IBS subtypes and age groups. Previously given drugs were besides diet (1 times), herbal preparations (Iberogast 
Tolerability, adverse events
Except for two out of 203 cases, patients and parents rated the overall tolerability of SF2 as good or better (98.6%). This is in nearly total agreement with the doctors rating of tolerability: except for two cases 98.5% of treatments were judged as good or better by the treating physician. No adverse events were noted.
Discussion
The irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that is characterized by a typical symptom constellation, i.e. abdominal pain or complaints associated with disturbed defecation. The diagnosis is based of confirmation of this typical symptom pattern, the missing of alarm symptoms (such as fever, weight loss, and blood with stools), and the exclusion of relevant differential diagnoses. This observational study used the recently published Rome III diagnostic criteria that have been adjusted to childhood functional bowel disorders [3] . It was investigated whether efficacy and tolerability of a probiotic preparation (SF2) can be found under routine conditions in private practice with children and whether this extends previous studies with the same or similar compounds in adults. Both physicians a well as parents and (adolescent) patients found the efficacy of the probiotic as good or better in the majority of cases (82% of physicians and 83% of patients) irrespective of the age group and the type of IBS. SF2 was regarded as better than previously used medication (acting on motility or as laxatives) for IBS in all but a few cases. Therefore, this observational study supplements the increasing number of previously conducted randomized double-blinded and placebo controlled treatment trials in IBS [10] using probiotic preparations that seem to be equivalent or even superior to newly developed chemical compounds for IBS treatment in recent years [14] , [15] , [16] , [17] . This is also confirmed by respective metaanalyses [18] , [19] , [20] , [21] . However, most of these studies have been conducted in adults with IBS. In comparison, only a few studies are available on probiotic treatment of childhood IBS [12] , [22] , [23] . Henker et al. [12] treated 113 children with acute diarrhea with an E. coli probiotic (Mutaflor ® ) in a placebocontrolled study and confirmed significant efficacy with respect to response rate, therapy goals and duration to achieve these goals. Bausserman et al. [22] treated 64 children with a lactobacillus GG preparation in comparison to placebo for 6 weeks and found that LGG improved bloating symptoms but not abdominal pain. Gawronska et al. [23] treated 103 children with a similar compound and found moderate therapy efficacy for IBS, but none for pure abdominal pain and functional upper gastrointestinal symptoms. A recent summary [24] of the respective published literature in children concluded that probiotics are not effective in constipation, and a Cochrane meta-analysis summarized that the data base for treatment of childhood IBS is altogether rather insufficient for a final conclusion [25] . Beyond lactobacillus preparations that are confirmed to be effective in adult treatment of IBS [20] , [21] , other bacterial strains have less frequently been used, and so far only one study has investigated the effects of an inactive E. coli bacterial preparation [26] , and another study successfully used a formula of non-living E. coli and Enterococcus feacalis bacteria [14] for therapy of IBS, in addition to the above discussed E. coli treatment of acute childhood diarrhea [12] . The relative homogeneous efficacy of different bacterial strains in the rather heterogeneous gastrointestinal disorder IBS in children and adults [10] calls for an answer to the questions of the underlying mechanism of action of prebiotics and probiotics [26] : It appears unlikely that this will be based on a temporary change of the commens-al colonic bacterial flora by new bacterial strains, as was often assumed previously, but instead relies on the stimulation of the innate intestinal immune system through novel bacteria that initiate long-lasting changes in intestinal function. This will have to be studied in the future. The limitations of the current study are obvious: as this is an observational study, it did not include a control group with either no treatment, or with a placebo treatment. Hence, the data are not controlled for spontaneous variation of symptoms and for a placebo response. Both are, however, known and effective factors contributing to the clinical appearance of symptoms in IBS [27] , [28] . Therefore, the efficacy data have to be interpreted with care. A comparison to "treatment as usual" (TAU) in childhood IBS may have allowed to overcome some of the study limitations without randomization into treatment arms as is would have allowed the doctor's decision to be based on clinical criteria only. Finally, while the study applied current diagnostic criteria for childhood IBS, it did not adopt the current standards for efficacy assessment in clinical trials based on "subjective global assessment" (SGA) in IBS, i.e. at least 50% improvement in SGA [29] and therefore may overrate the degree of clinical improvement. Final proof of the efficacy of probiotic treatment in childhood irritable bowel syndromes still requires a double-blinded, randomized and placebo controlled trial.
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Allgemeiner Ablauf, Dauer, Dosierung
Kinder im Alter von 4-11 Jahre und 12-18 Jahren mit Reizdarmsyndrom, die ohnehin mit Symbioflor-2 (SF2) (SymbioPharm, Herborn) behandelt wurden, sollten in die Anwendungsbeobachtung aufgenommen werden. Die 
Zu dokumentierende Symptomatik
Zu jedem Termin wurden das Vorhandensein und die Ausprägung folgender RDS-Symptome erhoben. Anzahl der Stühle (pro Tag oder pro Woche), Stuhlkonsistenz (hart/klumpig, geformt, breiig, flüssig, wechselnd), Stuhlbeimengung von Schleim (nein/ja), Bauchschmerzen (nein/ja), Meteorismus (nein/ja), Flatulenz (nein/ja), Stuhlpassage.
Biometrische Planung und Auswertung
Für die Auswertung wurden alle eingegangenen Erhebungsbogen herangezogen. Alle dokumentierten Patienten wurden in die Auswertung eingeschlossen ("intent-totreat" Analyse). Die dokumentierten Variablen wurden mit Kennzahlen der deskriptiven Statistik (arithmetisches Mittel, Standardabweichung, Minimum, Maximum, Median) dargestellt. Bei den qualitativen Merkmalen wurden Häufigkeitstabellen erstellt. Die inferenzstatistischen Methoden dienten ausschließlich der explorativen Analyse und sind nicht als konfirmatorische Beweise anwendbar. An der AWB nahmen 203 Kinder und Jugendliche der Altersgruppen 4-11 Jahre und 12-18 Jahre mit einem der vier klinischen Typen des Reizdarmsyndroms "Schmerz + Diarrhö", "Schmerz + Obstipation", "Schmerz + alternierend Diarrhö/Obstipation" und "Schmerz unspezifiziert" teil. Alle Patienten litten unter einem Reizdarmsyndrom entsprechend den ROM-III-Kriterien (Tabelle 3). Tabelle 3 zeigt deskriptive Kenngrößen des Geschlecht, Alters, der Größe und des Gewichts sämtlicher Patienten getrennt nach Altersgruppe und klinischem Typ des Reizdarmsyndroms. Es ergaben sich keine Unterschiede zwischen den vier klinischen Typen des Reizdarmsyndroms hinsichtlich des Geschlechtes, des Alters (p=0.4318), des Gewichts (p=0.9256, adjustiert bzgl. Alter) sowie der Größe der Patienten (p=0.5218, adjustiert bzgl. Alter). Die Diagnose eines RDS gemäß den ROM-III-Kriterien kann erst nach Beobachtung der Beschwerden über einen Mindestzeitraum von 2 Monaten gestellt werden. Entsprechend begannen die an dieser AWB teilnehmenden Ärzte in beiden Altersgruppen auch nach etwa 80 Tagen mit der Behandlung des Reizdarmsyndroms. Dabei bestanden relativ große Unterschiede zwischen den vier klinischen Typen: Generell wurden die Typen "Schmerz + Diarrhö" und "Schmerz + Obstipation" relativ frühzeitig therapiert, d.h. im Median nach weniger als 100 Tagen. Die klinischen Typen "Schmerz + alternierend Diarrhö/Obstipation" und "Schmerz unspezifiziert" wurden dagegen im Median erst nach mehr als 100 Tagen therapiert (Tabelle 3).
Dosierung von SF2, andere Arzneimitteln
Weit überwiegend verordneten die Prüfärzte mit 1-mal täglich 10 Tropfen die für Kinder empfohlene SF2-Standarddosierung: 77,4% aller Patienten erhielten diese Dosierung. Generell wurden selten (5% der Fälle) Dosisänderungen vorgenommen. Es haben insgesamt nur 6 Patienten andere Arzneimittel zur Behandlung des Reizdarmsyndroms parallel zur der Therapie mit SF2 erhalten, zumeist nur für wenige Tage: 4 x Lactulose, 1 x Gastrosil, 1 x Iberogast.
Dauer der Behandlung
Die mittlere Dauer der Therapie mit SF2 lag in beiden Altersgruppen und bei jedem klinischen Typ des Reizdarmsyndroms im Durchschnitt bei ca. 40-50 Tagen (Tabelle 3). Dabei stellt der klinische Typ "Schmerz unspezifiziert" in der Altersgruppe der 12-18-jährigen Patienten eine Ausnahme dar, die im Durchschnitt nur 34,2 Tage therapiert wurden. Die Unterschiede zwischen den beiden Altersgruppe und den vier klinischen Typen des Reizdarmsyndroms sind allerdings nicht statistisch signifikant (p=0.1919).
Wirksamkeit der Behandlung
Tabelle 4 zeigt die Wirksamkeit der SF2-Behandlung für die klinischen Kernparameter des Reizdarmsyndroms "Bauchschmerzen" und "Stuhlfrequenz" (s. oben) zwischen Eingangsuntersuchung und Abschlussuntersuchung, getrennt nach Altersgruppen und Symptomen. Die Änderungen sind signifikant (p<.001) Auch die Symptome "Meteorismus", "Flatulenz", Beimengung von Schleim im Stuhl, und veränderte Stuhlpassage (imperativer Stuhldrang, Notwendigkeit starken Pressens) 
Globale Beurteilung der Wirksamkeit
Tabelle 5 zeigt ebenfalls die globale Wirksamkeitsbewertung durch den Arzt. In der überwiegenden Mehrheit der Fälle wurde die Wirksamkeit der Therapie als "sehr gut" und "gut" bewertet (gesamt: 81,8%). Dies gilt für jede Altersgruppe und jeden klinischen Typ des Reizdarmsyndroms. Eine gewisse Ausnahme stellen dabei die 12-18-jährigen Patienten mit klinischem Typ "Schmerz + alternierend Diarrhö/Obstipation" dar, bei denen die Therapie in nur 55,5% der Fälle als "sehr gut" und "gut" bewertet wurde. Das Ergebnis relativiert sich allerdings durch die sehr geringe Fallzahl in der entsprechenden Subgruppe (9 Patienten), von denen bei nur 4 Patienten schlechtere Bewertungen abgegeben wurden.
Vergleich mit früher verwendeten Arzneimitteln
Nur ca. 40% der Patienten/Eltern machten hierzu Angaben, hatten also therapeutische Erfahrungen mit anderen Arzneimitteln zur Behandlung des Reizdarmsyndroms. SF2 wurde in der Mehrzahl der Fälle (77%) als besser bewertet wurde als andere, früher gegebene Arzneimittel, in nur wenigen Fällen wurde SF2 als "eher schlechter" als das Vergleichspräparat bewertet, nie als "viel schlechter". Es bestehen dabei keine signifikanten Unterschiede zwischen den vier klinischen Typen des Reizdarmsyndroms und zwischen beiden Altersgruppen. Die bekannten, früher bereits gegebenen anderen Arzneimittel waren (neben 1 x Diät) im Wesentlichen pflanzliche, die Motilität beeinflussende Mittel (Iberogast: 15x), Hefeprä-parate (Perenterol: 11x), und chemisch definierte Laxantien (Lactulose: 10x).
Verträglichkeit der Behandlung, Nebenwirkungen
Bis auf zwei Ausnahmen (befriedigend) der insgesamt 203 Fälle wurde die Verträglichkeit von SF2 von den Patienten/Eltern in 98,6% der Fälle als "sehr gut" und "gut" bewertet. Die Analyse der Verträglichkeitsbewertung durch die Patienten/Eltern stimmt qualitativ mit denen der ärztlichen Beurteilung überein: Bis auf zwei Ausnahmen der insgesamt 203 Fälle (1 x befriedigend; 1 x ausrei-chend) wurde die Verträglichkeit von SF2 in 98,5% als "sehr gut" und "gut" bewertet. Es wurden keine Nebenwirkungen dokumentiert. [10] , die eine Wirksamkeit zeigen, die der neu entwickelter Medikamente gleichwertig oder überle-gen ist [14] , [15] , [16] , [17] . Dies wird auch in Metaanalysen [18] , [19] , [20] , [21] bestätigt. Die meisten dieser Studien sind jedoch bei Erwachsenen durchgeführt worden. Dagegen sind bislang erst einige wenige kontrollierte Studien zur Wirksamkeit probiotischer Medikamente bei kindlichen funktionellen Magen-Darm-Erkrankungen berichtet worden [12] , [22] , [23] . Henker et al. [12] [25] . Jenseits der Laktobazillus-Präparationen, die in der Erwachsenenmedizin als gesichert wirksam gelten [20] , [21] , sind andere bakterielle Stämme selten eingesetzt worden, und es liegt bislang nur eine Studie vor, in der ein Probiotikum aus (abgetöteten) Escherichia coli eingesetzt wurde [26] , und eine weitere Studie, in der eine Mischung aus Escherichia coli-und Enterokokkus faecalisBakterien erfolgreich beim Reizdarmsyndrom eingesetzt wurde [14] , sowie die oben diskutierte Escherichia coliBehandlung bei kindlichen akuten Diarrhöen [12] . Die relativ homogene Wirksamkeit verschiedener Bakterienstämme bei dem eher heterogenen Krankheitsbild Reizdarmsyndrom bei Kindern und Erwachsenen [10] drängt die Frage nach dem Wirkmechanismus der Pround Präbiotika besonders auf [26] : Es ist unwahrscheinlich, dass dieser auf der zeitweiligen Veränderung der darmständigen Flora durch neue Stämme beruht, wie früher oftmals angenommen, sondern stattdessen auf der Stimulation des darmeigenen Immunsystems durch die Bakterien, um darüber eine anhaltende Wirkung zu entfalten. Dies wird Aufgabe zukünftiger Forschung sein. Die Beschränkungen dieser Studie sind offensichtlich: da es sich um eine Anwendungsbeobachtung handelt, wurde keine Kontrollgruppe eingeschlossen, die entweder keine Behandlung oder die ein Placebo erhalten hat. Daher sind die Ergebnisse nicht gegen den Spontanverlauf der Symptome oder gegen Placebowirkungen kontrolliert. Beide Phänomene tragen aber signifikant zu den klinischen Symptomen des RDS bei [27] , [28] . Daher müssen die Effizienzdaten mit Vorsicht interpretiert werden. Ein Vergleich mit der "üblichen Behandlung" (treatment as usual, TAU) des kindlichen Reizdarmsyndroms wäre eine weitere Möglichkeit gewesen, die Studienaussage zu verbessern, ohne dass dazu zwingend eine Randomisierung notwendig gewesen wäre, sondern die ausschließlich auf der Behandlungsentscheidung des Arztes basiert hätte. Schließlich hat die Studie zwar die gegenwärtigen Kriterien zur Diagnose eines kindlichen RDS benutzt, aber nicht die gegenwärtigen Standards zur Beurteilung eines Therapieerfolges nach "subjektiven globalen Kriterien" ("subjective global assessment", SGA), zum Beispiel eine mindestens 50%ige Besserung der SGA [29] ; daher mag diese Studien den Therapieerfolg überschätzen. Letztendlich kann nur eine randomisierte, doppelblinde und Placebo-kontrollierte Studie den Beweis für die Wirksamkeit probiotischer Behandlung des kindlichen Reizdarmsyndroms antreten.
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